1. Home
  2. GAU vs TECX Comparison

GAU vs TECX Comparison

Compare GAU & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galiano Gold Inc.

GAU

Galiano Gold Inc.

HOLD

Current Price

$1.98

Market Cap

606.0M

Sector

N/A

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$37.93

Market Cap

549.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAU
TECX
Founded
1999
2019
Country
Canada
United States
Employees
N/A
60
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
606.0M
549.5M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
GAU
TECX
Price
$1.98
$37.93
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$4.08
$75.20
AVG Volume (30 Days)
3.9M
128.2K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$82.77
N/A
Revenue Next Year
$29.09
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.26
$14.39
52 Week High
$3.62
$35.99

Technical Indicators

Market Signals
Indicator
GAU
TECX
Relative Strength Index (RSI) 43.86 73.51
Support Level $1.96 $27.31
Resistance Level $2.75 N/A
Average True Range (ATR) 0.10 2.07
MACD -0.00 0.62
Stochastic Oscillator 34.68 92.97

Price Performance

Historical Comparison
GAU
TECX

About GAU Galiano Gold Inc.

Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: